ab
Arbutus Biopharma
ABUS
NASDAQ $4.26
Does Arbutus Biopharma have high-quality management?
New leadership took over in 2025 with Lindsay Androski as CEO and Tuan Nguyen as CFO. The team executed a strategic refocus and supported successful settlement negotiations with Moderna through Genevant, but clinical execution under this team is still early.
Board refreshes and ties to Roivant/Genevant add IP monetization experience; however, an operating track record of advancing late‑stage pivotal studies and commercialization is not yet established.
Read the full report on Arbutus Biopharma and explore the other sections
Overview of Arbutus Biopharma
Does Arbutus Biopharma have a strong competitive moat?
Does Arbutus Biopharma have pricing power in its industry?
How predictable is Arbutus Biopharma's business?
Is Arbutus Biopharma financially strong?
How effective is Arbutus Biopharma's capital allocation strategy?
Does Arbutus Biopharma have high-quality management?
What is the fair value of Arbutus Biopharma stock?